Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Antivert

(Meclizine)

Phase 3Small molecule

Alnylam Pharmaceuticals

Meclizine is a medication that helps prevent and treat nausea, vomiting, and dizziness caused by motion sickness. It works best when taken before you start traveling or before symptoms begin.[1] Antivert is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]

Antivert is one of 110 small molecule programs targeting Vertigo. It is currently in Phase 3.

4

Indications

7

Total Trials

1

Active Trials

109

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

VertigoActive, not recruiting

Nausea and VomitingActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Smoking CessationActive, not recruiting

VertigoPhase 3

Active, not recruiting

Nausea and VomitingPreclinical

Active, not recruiting

Hepatocellular CarcinomaPhase 1

Active, not recruiting

Smoking CessationPhase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Antivert

Alnylam Pharmaceuticals

Ibrance

Viread

Sovaldi

Hepsera

Coreg

Akero Therapeutics

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Doptelet

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Vermox

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

ApprovedNot yet recruiting

Study completion

NCT07681076

Clinical

Trials by Indication[1]

Vertigo2 trials

Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients

Completed·LLehigh Valley Hospital·N/A·NCT00641797·26 enrolled

Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

Completed·AApsen Farmaceutica S.A.·Phase 3·NCT02112578·292 enrolled

Nausea and vomiting1 trial

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed·VVanderbilt University·N/A·NCT02625181·27,034 enrolled

Smoking Cessation1 trial

Meclizine as a Potential Smoking Cessation Treatment

Completed·—·Phase 2·NCT01443858·146 enrolled

Hepatocellular Carcinoma1 trial

Meclizine for Hepatocellular Carcinoma

Completed·TTannaz Armaghnay·Phase 1·NCT03253289·13 enrolled

Unspecified2 trials

The Effects of Antihistamines on Pre-Pulse Inhibition

Completed·—·Phase 1·NCT01537471·117 enrolled

A Phase 4, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Twice Daily Xanomeline/Trospium Chloride (KarXT) With Prophylactic and PRN Antiemetic Use in Healthy Volunteers

Not yet recruiting·KKaruna Therapeutics, Inc., a Bristol Myers Squibb company·Approved·NCT07681076·225 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

ANTIVERT

NDA NDA010721

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Meclizine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meclizine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meclizine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA010721). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Alnylam Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Alnylam Pharmaceuticals

Related News